Bargain hunters fire up rally in cannabis stocks
Send a link to a friend
[January 24, 2020] By
David Randall
NEW YORK (Reuters) - Some cannabis stocks
are seeing their prices surge as investors hunt for winners in the ashes
of an industry shakeout that hammered share prices last year.
Shares of Tilray Inc <TLRY.O> and Canopy Growth Corp <WEED.TO> have
climbed more than 20% since the start of the year, while Cronos Group
Inc <CRON.TO> and Aphria Inc <APHA.TO> are up more than 10%. The ETFMG
Alternative Harvest exchange-traded fund <MJ.P>, which targets the
global cannabis industry, is up 5.8% in that period.
A speculative "green rush" fueled by the legalization of cannabis in
Canada and some U.S. states faltered last year, as investors grew
worried about oversupply and whether companies could bring enough
customers out of the black market. Uncertainties over U.S. regulations
and revenue shortfalls further weighed on the sector.
Investors are now betting that some of these companies have become
undervalued. Canopy, for instance, trades 10% below the average target
price among the 22 analysts that cover it, according to Refinitiv data.
Its forward price-to-sales ratio, meanwhile, is at 16.4, well below its
peak of 32.1 it hit in January 2019 and more than double its low from
November.
"We went through the golden age and then we fell into the dark ages
where valuations were assuming that these companies were just dead,"
said Michael Underhill, chief investment officer at Capital Innovations.
Underhill’s fund owns shares of Canopy and is increasing its stake in
companies such as CBD beverage maker Alkaline Water Company Inc <WTER.O>,
cannabis financing company Ianthus Capital Holdings <IAN.CD>, and
multi-state cannabis operator Harvest Health & Recreation Inc <HARV.CD>.
Others are focusing on companies that are not pure plays on cannabis,
which they expect to better weather a tough regulatory environment in
the U.S.
Illinois this year became the 11th U.S. state, along with the District
of Columbia, to allow the recreational sale of cannabis. Yet a ballot
measure to legalize recreational use in Florida, the nation’s third
most-populous state, will likely not appear until at least 2022,
according to a note from research firm Jefferies.
[to top of second column] |
A worker shakes cocoa nibs into a machine during a tour at a Canopy
Growth facility that produces cannabis derivatives in Smiths Falls,
Ontario, Canada October 29, 2019. REUTERS/Blair Gable/File Photo
"Investors have realized that the rollout from a regulatory perspective isn't as
efficient as it should be," said Jason Wilson, who focuses on cannabis research
and banking at ETF Managers Group, which manages the $810 million ETFMG
Alternative Harvest ETF.
He is recommending shares of e-cigarette maker Turning Point Brands Inc <TPB.N>.
Dan Ahrens, portfolio manager of the $49 million actively-managed AdvisorShares
Pure Cannabis ETF <YOLO.P>, believes the sell-off in cannabis shares was
exacerbated by aggressive short-selling, or investors betting against the prices
of cannabis stocks.
He is focusing on smaller companies such as Innovative Industrial Properties Inc
<IIPR.N>, a real estate investment trust that leases greenhouses to grow
medical-use cannabis, and cultivators such as Village Farms International Inc <VFF.TO>
and OrganiGram Holdings Inc <OGI.TO. Short interest in both stocks has fallen by
half over the last six months.
At the same time, he is underweight large Canadian companies such as Tilray in
favor of companies that will focus more directly on the U.S. market.
There are "still too many companies in the space," he said. "Some will make it
and some won't."
(Graphic - Some fund managers now think cannabis stocks are undervalued:
https://fingfx.thomsonreuters.com/
gfx/editorcharts/USA-FUNDS-CANNABIS/
0H001QXY6BLB/index.html)
(Reporting by David Randall; Editing by Ira Iosebashvili and Nick Zieminski)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|